Outlook Therapeutics Inc

OTLKNASDAQ · USD
0.64USD0.00 (-2.49%)
1210

Outlook Therapeutics Inc (OTLK) Option Chain

As of September 25, 2026, Outlook Therapeutics Inc is trading at $0.64, a -2.49% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 281.0%. IV Rank is 46%.

Read more

Tracking the OTLK option chain helps you see every strike and expiry on Outlook Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Outlook Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of OTLK options activity at a glance. Use our scanner to monitor the OTLK option chain in real time and filter for the OTLK options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For OTLK stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the OTLK option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where OTLK stock options are being actively traded and where they are not.

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc.

and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Outlook Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen OTLK options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of OTLK stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile61.51% Neutral
  • Market cap (M$)156
  • 52 weeks high-74.80%
  • 52 weeks low300.00%
  • Analyst recommendationStrong Buy
    1.50
  • Target price$5.03
    685.94% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-12-18
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.09
  • EPS growth next 5 years—

As of September 25, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
48.4922000.010.140.050.250.50-21.88—0.050.000.050451.51
84.0914850.050.00—0.051.00+56.25—0.750.360.390715.91
94.571100.950.00—0.951.50+134.380.351.350.86-0.01005.43
97.90000.200.00—0.202.00+212.500.851.851.36-0.01012.10
99.10000.750.00—0.752.50+290.631.452.101.86-0.08000.90

As of September 25, 2026

Scan the full option chain in one place

Browse the full OTLK option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial